Clinical Trial

Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan

Completed
View on ClinicalTrials.gov →
Summary
This study will examine quality of life, experiences, and unmet needs among individuals diagnosed with Low Risk Myelodysplastic Syndrome who are erythropoietin stimulating agent naïve and non-transfusion dependent and among individuals with suspected myelodysplastic syndromes with unexplained anemia in Japan
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-29; most recent amendment 2026-05-21.
Status change: Recruiting → Completed 2026-05-21
Trial Details
NCT Number NCT07008820
Lead Sponsor Bristol-Myers Squibb
Conditions Myelodysplastic Syndrome (MDS)
Enrollment 56 participants
Start Date 2025-05-13
Primary Completion 2026-02-24 (estimated)
Study Completion 2026-02-24 (estimated)
Updated on ClinicalTrials.gov 2026-05-26